|
業務類別
|
Biotechnology |
|
業務概覽
|
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to restore healthy immune balance in patients with alopecia areata (AA) and other autoimmune and inflammatory diseases driven by immune dysfunction. Its product candidate, bempikibart (ADX 914), is a fully human anti-interleukin 7 receptor alpha (IL-7R) antagonist monoclonal antibody designed to block signaling mediated by interleukin 7 (IL 7) and thymic stromal lymphopoietin (TSLP) and re-regulate adaptive immune function. The company has completed two Phase 2a clinical trials evaluating bempikibart, SIGNAL AA Part A for the treatment of alopecia areata and SIGNAL AD for the treatment of atopic dermatitis (AD). |
| 公司地址
| 830 Winter Street, Waltham, MA, USA, 02451 |
| 電話號碼
| +1 718 999-0232 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.q32bio.com |
| 員工數量
| 24 |
| Dr. Shelia M. Violette, PhD |
Chief Scientific Officer and President, Research |
-- |
29/04/2025 |
| Ms. Adrien Sipos, M.D. |
Interim Chief Medical Officer |
-- |
25/06/2025 |
| Mr. Lee Kalowski, M.B.A. |
Chief Financial Officer, President and Principal Accounting Officer |
美元 432.44K |
10/03/2026 |
| Ms. Jodie P. Morrison |
Chief Executive Officer and Director |
美元 627.11K |
10/03/2026 |
|
|
| Dr. Isaac Manke, PhD |
Independent Director |
10/03/2026 |
| Dr. Arthur O. Tzianabos, PhD |
Director |
10/03/2026 |
| Dr. David S. Grayzel, M.D. |
Independent Director |
10/03/2026 |
| Dr. Bill Lundberg |
Independent Director |
10/03/2026 |
| Ms. Mary T. Thistle |
Independent Director |
10/03/2026 |
| Ms. Jodie P. Morrison |
Chief Executive Officer and Director |
10/03/2026 |
| Ms. Kathleen D. Laporte |
Independent Director |
10/03/2026 |
| Mr. Diyong Xu |
Independent Director |
10/03/2026 |
|
|
|
|
